<DOC>
	<DOC>NCT02957630</DOC>
	<brief_summary>The proposed study will provide an assessment of the effect of this combination on endocrine function, metabolic control and hemostasis during 6 treatment cycles. This will be compared to the effects of two reference COCs.</brief_summary>
	<brief_title>"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Healthy adult woman Negative pregnancy test at subject screening and randomization Aged 1850 years (inclusive) at the time of signing the ICF Good physical and mental health on the basis of medical, surgical and gynecological history, physical examination, gynecological examination, clinical laboratory, ECG, echocardiography and vital signs BMI from 18.0 to 30.0 kg/m², inclusive, at time of screening visit Able to fulfil the requirements of the protocol and have indicated a willingness to participate in the study by providing written informed consent Known hypersensitivity to any of the investigational product ingredients Smoking if &gt; 35 years old Dyslipoproteinemia or use of antilipidemic agent Known diabetes mellitus Current use of antidiabetic drugs, including insulin Arterial hypertension Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism. Any condition associated with abnormal uterine/vaginal bleeding. Presence of an undiagnosed breast mass Current symptomatic gallbladder disease History of pregnancy or COCrelated cholestasis Presence or history of severe hepatic disease Presence or history of pancreatitis if associated with hypertriglyceridemia Porphyria Presence or history of benign liver tumors (focal nodular hyperplasia and hepatocellular adenoma) Presence of renal impairment (glomerular filtration rate [GFR] &lt;60 mL/min/1.73m²) Hyperkalemia or presence of conditions that predispose to hyperkalemia Presence or history of hormonerelated malignancy History of nonhormonerelated malignancy within 5 years before screening; subjects with a nonmelanoma skin cancer are allowed in the study Use of drugs potentially triggering interactions with COCs History of alcohol or drug abuse within 12 months prior to screening Presence or history of thyroid disorders Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to randomization. Subjects who participated in an oral contraceptive clinical study using Food and Drug Administration (FDA)/European Union (EU) approved active ingredients, may be randomized 2 months (60 days) after completing the preceding study Sponsor, contract research organization (CRO) or Principal Investigator's (PI's) site personnel directly affiliated with this study Is judged by the PI to be unsuitable for any reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Estetrol (E4)</keyword>
	<keyword>Drospirenone (DRSP)</keyword>
	<keyword>Ethinylestradiol (EE)</keyword>
	<keyword>Levonorgestrel (LNG)</keyword>
	<keyword>Oral contraceptive</keyword>
	<keyword>Prevention of pregnancy</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Metabolism</keyword>
</DOC>